ClinicalTrials.gg
CompletedNCT03743766Updated Aug 31, 2026Results posted

Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting

A Phase 2 interventional study of Relatlimab and Nivolumab in Melanoma, sponsored by John Kirkwood. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by John Kirkwood · Phase 2, Interventional, and Treatment

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing relatlimab in Melanoma — 6 open to participants now, 10 under way, 1 of them phase 3. relatlimab · Melanoma.

Enrollment
9th of 16
43 · median 48
Started
2019
with 1 other
Phase 2
10 of 16
4 open now
Registered
3rd of 16
by date
Lead sponsor
1 of 16
John Kirkwood

Among the 16 studies testing relatlimab in Melanoma, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 10 in phase 2, and was the 3rd registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

6 of the 16 studies testing relatlimab in Melanoma are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About relatlimab

relatlimab: first FDA approval 2022 (OPDUALAG), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing relatlimab in Melanoma, or all of them as a file.
02

Study summary

The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.

Read the detailed description

This study will evaluate the antitumor activity of anti-LAG3 monoclonal antibody relatlimab and the anti-PD1 monoclonal antibody nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy. The trial is designed with a lead-in phase of 2 cycles (4 week) treatment of either nivolumab, relatlimab, or the combination of nivolumab/relatlimab, followed by a combination phase of nivolumab/relatlimab treatment in all subjects. This lead-in design with accompanying tumor biopsies and peripheral blood analyses will enable mechanistic analyses of the effect of LAG3 and PD1 blockade alone and in combination to enhance understanding of mechanisms of response and resistance. Duration of response, progression free survival, and safety will be assessed as secondary objectives.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Stage IIIB
  • Stage IIIC
  • Stage IIID
  • Stage IV
  • immune checkpoint blockade (ICB)
  • Lymphocyte activation gene-3 (LAG3; CD223)
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women 18 years of age or older meeting AJCC 8th edition criteria for unresectable stage IIIB, stage IIIC, stage IIID, or stage IV melanoma who have not received treatment with immunotherapy in the setting

Exclusion criteria

Exclusion Criteria:

  • Known or suspected , with the following exceptions:

    • Subjects with controlled brain metastases will be allowed to enroll. Controlled brain metastases are defined as no radiographic progression for at least 4 weeks following radiation and/or surgical treatment at the time of consent. Subjects must be off for at least 2 weeks prior to randomization.
    • Subjects with signs or symptoms of brain metastases are not eligible unless brain metastases are ruled out by computed tomography or magnetic resonance imaging.
  • Active disease requiring treatment, with the exception of type 1 diabetes mellitus, vitiligo, resolved childhood asthma/atopy, controlled hyper/hypothyroidism, hypoadrenalism or hypopituitarism.
  • Prior systemic treatment in the setting, including anti-PD1, anti-PDL1, anti-PDL2, antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways; or chemotherapy.
  • Prior treatment with anti-PD1, anti-PDL1, and/or anti-LAG3 antibody. Note that prior adjuvant treatment with targeted therapy (e.g. BRAF/MEK inhibition), anti-CTLA4, or treatment not otherwise specified above would be permitted.
  • Ocular melanoma
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Relatlimab

    Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1). Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks.

    Drug: Relatlimab

  • Experimental
    Nivolumab

    Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks. Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks.

    Drug: Nivolumab

  • Experimental
    Relatlimab + Nivolumab

    Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.

    Drug: Relatlimab + Nivolumab

Interventions

  • Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.

    Also known as: BMS-986016

  • Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.

    Also known as: BMS-936558

  • DrugRelatlimab + Nivolumab

    Drug pages: RelatlimabStudies of RelatlimabRelatlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.

    Also known as: BMS-986016 and BMS-936558

06

What researchers measure

Primary outcomes

  1. LAG3 Gene Expression From scRNAseq

    Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq

    Time frame: At Baseline

  2. LAG3 Gene Expression From scRNAseq

    Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq

    Time frame: At Week 4

  3. PD1 Expression

    Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.

    Time frame: At baseline (Week 0)

  4. PD1 Expression

    Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.

    Time frame: At Week 4

  5. Change in Tumor Size

    Percentage change in tumor size assessed per Response Evaluation Criteria in Solid Tumors. Per RECIST 1.1, Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: * 10 mm by CT scan (CT scan slice thickness no greater than 5 mm; see Appendix II on imaging guidance). * 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable). * 20 mm by chest X-ray.

    Time frame: At baseline and at 4 weeks

  6. Overall Response Rate (ORR)

    Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Beginning at 12 weeks post initial treatment, up to 4 years

  7. Overall Response Rate (ORR) - ITT (Intent-to-treat) Population

    Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Beginning at 12 weeks post initial treatment, up to 4 years

Secondary outcomes

  1. Secondary Outcome: Clinical Benefit Rate

    Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: 12 weeks post initial treatment, up to 4 years

  2. Clinical Benefit Rate - ITT (Intent-to-treat) Population

    Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: 12 weeks post initial treatment, up to 4 years

  3. Duration of Response

    Time from first documented Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: 12 weeks post initial treatment, up to 4 years

  4. Progression-free Survival (PFS)

    Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 4 years

  5. Progression-free Survival (PFS) by Lead-in Arm

    Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 4 years

  6. Overall Survival (OS)

    Overall survival is defined as the time between the date of randomization and the date of death due to any cause.

    Time frame: Up to 4 years

  7. CD8+ Tumor Infiltrating Lymphocytes

    Number of CD8+ tumor infiltrating lymphocytes present.

    Time frame: At Baseline

  8. CD8+ Tumor Infiltrating Lymphocytes

    Number of CD8+ tumor infiltrating lymphocytes present.

    Time frame: At Week 4

  9. CD4+ Tumor Infiltrating Lymphocytes

    Number of CD4+ tumor infiltrating lymphocytes present.

    Time frame: At Week 4

  10. CD4+ Tumor Infiltrating Lymphocytes

    Number of CD4+ tumor infiltrating lymphocytes present.

    Time frame: At Baseline

  11. LAG3 Levels - PBMC

    To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Baseline

  12. LAG3 Levels - PBMC

    To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 4

  13. LAG3 Levels - TIL

    To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Baseline

  14. LAG3 Levels - PBMC

    To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 16

  15. LAG3 Levels - TIL

    To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 4

  16. PD-1 Expression in PBMC

    To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Baseline

  17. PD-1 Expression in PBMC

    To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 4

  18. PD-1 Expression in PBMC

    To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 16

  19. PD-1 Expression in TIL

    To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Baseline

  20. PD-1 Expression in TIL

    To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

    Time frame: At Week 4

  21. Cell Effector/Memory Status - TIL

    Measure of cells that have previously encountered and responded to their cognate antigen in TIL.

    Time frame: At Baseline

  22. Cell Effector/Memory Status - TIL

    Measure of cells that have previously encountered and responded to their cognate antigen in TIL.

    Time frame: At Week 4

  23. Cell Effector/Memory Status - PBMCs

    Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

    Time frame: At Baseline

  24. Cell Effector/Memory Status - PBMC

    Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

    Time frame: At Week 4

  25. Cell Effector/Memory Status - PBMC

    Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

    Time frame: At Week 16

  26. Regulatory T Cell (Treg) Marker Levels - PMBCs

    Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

    Time frame: At Baseline

  27. Regulatory T Cell (Treg) Marker Levels - PMBCs

    Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

    Time frame: At Week 4

  28. Regulatory T Cell (Treg) Marker Levels - PMBCs

    Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

    Time frame: At Week 16

  29. Regulatory T Cell (Treg) Marker Levels - TIL

    Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.

    Time frame: At Baseline

  30. Regulatory T Cell (Treg) Marker Levels - TIL

    Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.

    Time frame: At Week 4

  31. Activation and Maturation of Dendritic Cells - PBMC

    Measure of expression of activation and maturation of dendritic cells in PBMCs.

    Time frame: At Baseline

  32. Activation and Maturation of Dendritic Cells - PBMC

    Measure of expression of activation and maturation of dendritic cells in PBMCs.

    Time frame: At Week 4

  33. Activation and Maturation of Dendritic Cells - PBMC

    Measure of expression of activation and maturation of dendritic cells in PBMCs.

    Time frame: At Week 16

  34. Activation and Maturation of Dendritic Cells - TIL

    Measure of expression of activation and maturation of dendritic cells in tumor (TIL).

    Time frame: At Baseline

  35. Activation and Maturation of Dendritic Cells - TIL

    Measure of expression of activation and maturation of dendritic cells in tumor (TIL).

    Time frame: At Week 4

  36. Soluble LAG3 Levels - PBMC

    Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in blood in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: At the time of disease progression - up to 4 years

  37. Soluble LAG3 Levels - TIL

    Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: At the time of disease progression - up to 4 years

  38. Granzyme B Serum Levels

    Level of granzyme B (a serine protease secreted cells to mediate apoptosis in target cells) in serum.

    Time frame: At 2 weeks prior first study treatment, at 4 weeks, at 12 weeks

  39. T Cell Count

    Number of T cells present in TIL or PBMC.

    Time frame: At 4 weeks

  40. T Cell Count

    Number of T cells present in TIL or PBMC.

    Time frame: At 12 weeks

  41. T Cell Count

    Number of T cells present in TIL or PBMC.

    Time frame: At the time of disease progression - up to 4 years

Other outcomes

  1. Single Cell RNA Sequencing

    The presence and quantity of RNA in in blood and tumor tissue.

    Time frame: 2 weeks

  2. Single Cell RNA Sequencing

    The presence and quantity of RNA in in blood and tumor tissue.

    Time frame: At 4 weeks post Cycle 1

  3. Single Cell RNA Sequencing

    The presence and quantity of RNA in in blood and tumor tissue.

    Time frame: At week 16 (12 weeks post combination treatment (3 cycles)

  4. Single Cell RNA Sequencing

    The presence and quantity of RNA in in blood and tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: At the time of disease progression - up to 4 years

07

Results

Posted Aug 31, 2026

Participant flow

Participant flow — Overall Study
MilestoneRelatlimabNivolumabRelatlimab + Nivolumab
Started141514
Completed141514
Not completed000

Outcome measures

PrimaryLAG3 Gene Expression From scRNAseq

Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq

Time frame:
At Baseline
Reported as:
Mean · percent
LAG3 Gene Expression From scRNAseq
percentRelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Gene Expression From scRNAseq0.78 ± 1.272.94 ± 4.289.37 ± 10.93
PrimaryLAG3 Gene Expression From scRNAseq

Percent Lymphocyte-activation gene 3 (LAG3) level (cell surface molecule expressed on activated T cells) expression from scRNAseq

Time frame:
At Week 4
Reported as:
Mean · percent
LAG3 Gene Expression From scRNAseq
percentRelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Gene Expression From scRNAseq0.96 ± 2.0113.12 ± 22.0213.50 ± 9.31
Statistical analysis
  • Relatlimab · Wilcoxon (Mann-Whitney) · p = 1.00 (adjusted p-value (Bonferroni Method))
  • Nivolumab · Wilcoxon (Mann-Whitney) · p = 0.16 (adjusted p-value (Bonferroni Method))
  • Relatlimab + Nivolumab · Wilcoxon (Mann-Whitney) · p = 1.00
PrimaryPD1 Expression

Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.

Time frame:
At baseline (Week 0)
Reported as:
Mean · percent
PD1 Expression
percentRelatlimabNivolumabRelatlimab + Nivolumab
PD1 Expression9.29 ± 14.775.43 ± 5.0912.28 ± 9.47
PrimaryPD1 Expression

Percent PD1 (programmed cell death protein 1) expression after completion of lead-in phase.

Time frame:
At Week 4
Reported as:
Mean · percent
PD1 Expression
percentRelatlimabNivolumabRelatlimab + Nivolumab
PD1 Expression2.91 ± 3.115.78 ± 4.786.19 ± 5.09
Statistical analysis
  • Relatlimab · Wilcoxon (Mann-Whitney) · p = 1.00adjusted p-value (Bonferroni Method)
  • Nivolumab · Wilcoxon (Mann-Whitney) · p = 1.00adjusted p-value (Bonferroni Method)
  • Relatlimab + Nivolumab · Wilcoxon (Mann-Whitney) · p = 0.16adjusted p-value (Bonferroni Method)
PrimaryChange in Tumor Size

Percentage change in tumor size assessed per Response Evaluation Criteria in Solid Tumors. Per RECIST 1.1, Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: * 10 mm by CT scan (CT scan slice thickness no greater than 5 mm; see Appendix II on imaging guidance). * 10 mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable). * 20 mm by chest X-ray.

Time frame:
At baseline and at 4 weeks
Reported as:
Median · percent change
Change in Tumor Size
percent changeRelatlimabNivolumabRelatlimab + Nivolumab
Change in Tumor Size10 (-2 to 28)3 (-8 to 18)-5 (-6 to 1)
Statistical analysis
  • Relatlimab vs Nivolumab vs Relatlimab + Nivolumab · ANOVA · p = 0.00226995 (The restricted cubic spline model was evaluated using an F-test from the ANOVA table. A significant association between changes in cell density and the outcome (change in tumor size) was considered present.)F-test from the ANOVA
  • Relatlimab vs Nivolumab vs Relatlimab + Nivolumab · ANOVA · p = 0.4523263 (The restricted cubic spline model was evaluated using an F-test from the ANOVA table. A significant association between changes in cell density and the outcome (change in tumor size) was considered present.)F-test from the ANOVA
PrimaryOverall Response Rate (ORR)

Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Beginning at 12 weeks post initial treatment, up to 4 years
Reported as:
Number · percentage of patients
Overall Response Rate (ORR)
percentage of patientsRelatlimabNivolumabRelatlimab + Nivolumab
Overall Response Rate (ORR)20 (3.68 to 50.69)50 (26.36 to 73.64)46.15 (22.4 to 71.3)
PrimaryOverall Response Rate (ORR) - ITT (Intent-to-treat) Population

Percent of participants experiencing Complete Response (CR) + Number of participants experiencing Partial Response (PR)/total patients assessed. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
Beginning at 12 weeks post initial treatment, up to 4 years
Reported as:
Number · percentage of patients
Overall Response Rate (ORR) - ITT (Intent-to-treat) Population
percentage of patientsRelatlimabNivolumabRelatlimab + Nivolumab
Overall Response Rate (ORR) - ITT (Intent-to-treat) Population14.29 (2.6 to 38.54)46.67 (24.37 to 70)42.86 (20.61 to 67.5)
SecondarySecondary Outcome: Clinical Benefit Rate

Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
12 weeks post initial treatment, up to 4 years
Reported as:
Number · Percentage
Secondary Outcome: Clinical Benefit Rate
PercentageRelatlimabNivolumabRelatlimab + Nivolumab
Secondary Outcome: Clinical Benefit Rate80 (49.31 to 96.32)78.57 (53.43 to 93.89)76.92 (50.54 to 93.4)
SecondaryClinical Benefit Rate - ITT (Intent-to-treat) Population

Percent of patients with Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) / total patients assessed per RECIST v1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
12 weeks post initial treatment, up to 4 years
Reported as:
Number · Percentage
Clinical Benefit Rate - ITT (Intent-to-treat) Population
PercentageRelatlimabNivolumabRelatlimab + Nivolumab
Clinical Benefit Rate - ITT (Intent-to-treat) Population57.14 (32.5 to 79.39)73.33 (48.92 to 90.33)71.43 (46 to 89.6)
SecondaryDuration of Response

Time from first documented Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented. Per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
12 weeks post initial treatment, up to 4 years
Reported as:
Median · months
Duration of Response
monthsRelatlimabNivolumabRelatlimab + Nivolumab
Duration of ResponseNA (22.4 to NA)NA (37.5 to NA)NA (NA to NA)
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 4 years
Reported as:
Median · months
Progression-free Survival (PFS)
monthsRelatlimabNivolumabRelatlimab + Nivolumab
Progression-free Survival (PFS)1.9 (0.9 to NA)4.7 (1.0 to NA)14.7 (9.1 to NA)
SecondaryProgression-free Survival (PFS) by Lead-in Arm

Progression-free survival is defined as the time between the date of randomization and the first date of documented progression or death due to any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 4 years
Reported as:
Median · months
Progression-free Survival (PFS) by Lead-in Arm
monthsRelatlimabNivolumabRelatlimab + Nivolumab
Progression-free Survival (PFS) by Lead-in Arm1.9 (0.9 to NA)4.7 (1.0 to NA)14.7 (9.1 to NA)
SecondaryOverall Survival (OS)

Overall survival is defined as the time between the date of randomization and the date of death due to any cause.

Time frame:
Up to 4 years
Reported as:
Median · months
Overall Survival (OS)
monthsRelatlimabNivolumabRelatlimab + Nivolumab
Overall Survival (OS)23.6 (12.1 to NA)41.1 (19.0 to NA)NA (27.7 to NA)
SecondaryCD8+ Tumor Infiltrating Lymphocytes

Number of CD8+ tumor infiltrating lymphocytes present.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
CD8+ Tumor Infiltrating Lymphocytes
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
CD8+ Tumor Infiltrating Lymphocytes0.410590278 (0.143863179 to 0.513750731)0.359393872 (0.2011635366359 to 0.549686402)0.36241623 (0.200645966 to 0.4794291948955)
SecondaryCD8+ Tumor Infiltrating Lymphocytes

Number of CD8+ tumor infiltrating lymphocytes present.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
CD8+ Tumor Infiltrating Lymphocytes
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
CD8+ Tumor Infiltrating Lymphocytes0.496584699 (0.451612903 to 0.5733944954128)0.382900483 (0.271371353 to 0.47105706)0.519125683 (0.4189190000300 to 0.6266313145408)
SecondaryCD4+ Tumor Infiltrating Lymphocytes

Number of CD4+ tumor infiltrating lymphocytes present.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
CD4+ Tumor Infiltrating Lymphocytes
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
CD4+ Tumor Infiltrating Lymphocytes0.23392283 (0.150561798 to 0.281420765)0.194253553 (0.058145753 to 0.2949838417982)0.220195639 (0.175148548 to 0.257110926)
SecondaryCD4+ Tumor Infiltrating Lymphocytes

Number of CD4+ tumor infiltrating lymphocytes present.

Time frame:
At Baseline
Reported as:
Mean · proportion of immune cells
CD4+ Tumor Infiltrating Lymphocytes
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
CD4+ Tumor Infiltrating Lymphocytes0.221945137 (0.136363636 to 0.32193159)0.236556234 (0.2097374566643 to 0.277051228)0.24424409 (0.213976252 to 0.392482686)
SecondaryLAG3 Levels - PBMC

To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Baseline
Reported as:
Median · ln(LAG3 transcripts/totalmappedreads+1)
LAG3 Levels - PBMC
ln(LAG3 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Levels - PBMC117.4181801 (61.54439729 to 294.4849249)87.41155574 (47.96758893 to 142.8924017)81.63475936 (70.23308523 to 142.5931631)
SecondaryLAG3 Levels - PBMC

To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 4
Reported as:
Median · ln(LAG3 transcripts/totalmappedreads+1)
LAG3 Levels - PBMC
ln(LAG3 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Levels - PBMC24.413734087489 (9.3474180371759 to 62.236318580783)85.234642328843 (18.302744806527 to 153.60255356972)114.21499509798 (38.868567296591 to 207.59732584449)
SecondaryLAG3 Levels - TIL

To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Baseline
Reported as:
Median · ln(LAG3 transcripts/totalmappedreads+1)
LAG3 Levels - TIL
ln(LAG3 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Levels - TIL553.0461253 (41.26380993 to 1527.474199)781.0925834 (227.8971686 to 2620.194512)294.6551121 (48.9453378 to 671.3791451)
SecondaryLAG3 Levels - PBMC

To determine the amount of LAG3 expressed on activated T cells in the blood through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 16
Reported as:
Median · ln(LAG3 transcripts/totalmappedreads+1)
LAG3 Levels - PBMC
ln(LAG3 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Levels - PBMC78.30750135 (39.7607976 to 105.623955)208.2743213 (92.76860627 to 403.4555187)115.7683188 (82.53645799 to 186.7920792)
SecondaryLAG3 Levels - TIL

To determine the amount of LAG3 expressed on activated tumor infiltrating lymphocytes (TIL) through single-cell RNA sequencing. The LAG3 expression is reported as the natural log (ln) of the number of LAG3 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 4
Reported as:
Median · ln(LAG3 transcripts/totalmappedreads+1)
LAG3 Levels - TIL
ln(LAG3 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
LAG3 Levels - TIL484.95998714484 (349.03637689208 to 673.13564639344)181.73348534061 (108.66150695992 to 280.97789375502)191.56231622054 (101.93016786268 to 1468.6099534725)
SecondaryPD-1 Expression in PBMC

To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Baseline
Reported as:
Mean · ln(PD-1 transcripts/totalmappedreads+1)
PD-1 Expression in PBMC
ln(PD-1 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
PD-1 Expression in PBMC35.71568809 (16.03550284 to 57.00538064)21.75600549 (15.15743416 to 35.4023936)25.26034324 (18.6050362 to 42.22906242)
SecondaryPD-1 Expression in PBMC

To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 4
Reported as:
Mean · ln(PD-1 transcripts/totalmappedreads+1)
PD-1 Expression in PBMC
ln(PD-1 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
PD-1 Expression in PBMC4.395254969 (1.524867838 to 27.44315979)32.91097578 (15.04585236 to 60.3081099)37.82897218 (11.0244881 to 69.37037671)
SecondaryPD-1 Expression in PBMC

To determine the amount of PD-1 (programmed cell death protein 1) expressed on PBMCs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 16
Reported as:
Mean · ln(PD-1 transcripts/totalmappedreads+1)
PD-1 Expression in PBMC
ln(PD-1 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
PD-1 Expression in PBMC28.53794861 (13.86309395 to 51.9408153)88.7381496 (39.56943112 to 178.7760098)59.92440919 (38.9608126 to 96.098883)
SecondaryPD-1 Expression in TIL

To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Baseline
Reported as:
Mean · ln(PD-1 transcripts/totalmappedreads+1)
PD-1 Expression in TIL
ln(PD-1 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
PD-1 Expression in TIL230.9153184 (27.24279784 to 489.0740512)449.2734698 (168.6028866 to 885.1304368)239.7028054 (28.36920071 to 407.0256233)
SecondaryPD-1 Expression in TIL

To determine the amount of PD-1 (programmed cell death protein 1) expressed on TILs through single-cell RNA sequencing in treated patients. The PD-1 expression is reported as the natural log (ln) of the number of PD-1 transcripts divided by the number of total mapped reads plus 1.

Time frame:
At Week 4
Reported as:
Median · ln(PD-1 transcripts/totalmappedreads+1)
PD-1 Expression in TIL
ln(PD-1 transcripts/totalmappedreads+1)RelatlimabNivolumabRelatlimab + Nivolumab
PD-1 Expression in TIL228.75905461118 (29.378008590205 to 314.54965409338)52.286295752816 (25.095455416135 to 118.50159633512)97.373785446401 (54.125072015474 to 723.67240171323)
SecondaryCell Effector/Memory Status - TIL

Measure of cells that have previously encountered and responded to their cognate antigen in TIL.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Cell Effector/Memory Status - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
memory0.032769556 (0.022393822 to 0.055555556)0.04014046 (0.026397003 to 0.079803468)0.072042923 (0.020349099 to 0.219567669)
effector0.005644028 (0.003943448 to 0.069638695)0.004836982 (0.003384551 to 0.011538082)0.00315595 (0.002346804 to 0.00571541)
SecondaryCell Effector/Memory Status - TIL

Measure of cells that have previously encountered and responded to their cognate antigen in TIL.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Cell Effector/Memory Status - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
memory0.024393456 (0.018188142 to 0.036117078)0.050310559 (0.024560063 to 0.069113471)0.027002762 (0.017210365 to 0.041072618)
effector0.003741315 (0.002638522 to 0.008)0.007784912 (0.003288969 to 0.00921277)0.006480295 (0.002192184 to 0.015131579)
SecondaryCell Effector/Memory Status - PBMCs

Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Cell Effector/Memory Status - PBMCs
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
memory0.173913043 (0.076345432 to 0.245737212)0.137828185 (0.113406637 to 0.181557067)0.198312236 (0.121602932 to 0.305413895)
effector0.029087262 (0.007633588 to 0.078760491)0.023693761 (0.018095238 to 0.033324224)0.01420765 (0.013335198 to 0.040356548)
SecondaryCell Effector/Memory Status - PBMC

Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Cell Effector/Memory Status - PBMC
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
memory0.199023648 (0.141758242 to 0.273277512)0.162300324 (0.078517448 to 0.243674507)0.171945701 (0.089264386 to 0.347987251)
effector0.025974026 (0.019073923 to 0.046315789)0.011019284 (0.009361856 to 0.023844932)0.029145316 (0.014079027 to 0.038629997)
SecondaryCell Effector/Memory Status - PBMC

Measure of cells that have previously encountered and responded to their cognate antigen in PBMCs.

Time frame:
At Week 16
Reported as:
Median · proportion of immune cells
Cell Effector/Memory Status - PBMC
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
memory0.26744186 (0.224274406 to 0.464285714)0.181510619 (0.0847756 to 0.375080749)0.184960054 (0.11202629 to 0.250726645)
effector0.026155752 (0.018633783 to 0.040069648)0.010531062 (0.006688079 to 0.01555367)0.010721374 (0.007409468 to 0.020016729)
SecondaryRegulatory T Cell (Treg) Marker Levels - PMBCs

Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Regulatory T Cell (Treg) Marker Levels - PMBCs
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Regulatory T Cell (Treg) Marker Levels - PMBCs0.031311275 (0.027668814 to 0.039353362)0.032663631 (0.025531943 to 0.038065535)0.025919732 (0.013928831 to 0.041448479)
SecondaryRegulatory T Cell (Treg) Marker Levels - PMBCs

Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Regulatory T Cell (Treg) Marker Levels - PMBCs
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Regulatory T Cell (Treg) Marker Levels - PMBCs0.027264981 (0.017635861 to 0.051930576)0.047009262 (0.036717905 to 0.052503788)0.046875 (0.027912065 to 0.053002957)
SecondaryRegulatory T Cell (Treg) Marker Levels - PMBCs

Amount of Regulatory T cell (Treg) markers present in PBMCs in treated patients.

Time frame:
At Week 16
Reported as:
Median · proportion of immune cells
Regulatory T Cell (Treg) Marker Levels - PMBCs
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Regulatory T Cell (Treg) Marker Levels - PMBCs0.056900222 (0.028511821 to 0.075614489)0.044996348 (0.036690206 to 0.049494691)0.038493371 (0.03643035 to 0.045096718)
SecondaryRegulatory T Cell (Treg) Marker Levels - TIL

Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Regulatory T Cell (Treg) Marker Levels - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Regulatory T Cell (Treg) Marker Levels - TIL0.05866008 (0.036024306 to 0.093516209)0.058558335 (0.047202783 to 0.079397021)0.067705317 (0.047454931 to 0.098647656)
SecondaryRegulatory T Cell (Treg) Marker Levels - TIL

Amount of Regulatory T cell (Treg) markers present in TILs in treated patients.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Regulatory T Cell (Treg) Marker Levels - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Regulatory T Cell (Treg) Marker Levels - TIL0.056949153 (0.042696629 to 0.074121289)0.026785714 (0.016600266 to 0.063822859)0.065735998 (0.049323821 to 0.097586207)
SecondaryActivation and Maturation of Dendritic Cells - PBMC

Measure of expression of activation and maturation of dendritic cells in PBMCs.

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Activation and Maturation of Dendritic Cells - PBMC
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Activation and Maturation of Dendritic Cells - PBMC0.03070015 (0.021834008 to 0.041250195)0.036025924 (0.021281652 to 0.048815284)0.030824639 (0.014091698 to 0.0473892638630)
SecondaryActivation and Maturation of Dendritic Cells - PBMC

Measure of expression of activation and maturation of dendritic cells in PBMCs.

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Activation and Maturation of Dendritic Cells - PBMC
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Activation and Maturation of Dendritic Cells - PBMC0.03922571 (0.03139739 to 0.058189597)0.048762416 (0.039213563 to 0.087995338)0.035719581 (0.012278647 to 0.038502674)
SecondaryActivation and Maturation of Dendritic Cells - PBMC

Measure of expression of activation and maturation of dendritic cells in PBMCs.

Time frame:
At Week 16
Reported as:
Median · proportion of immune cells
Activation and Maturation of Dendritic Cells - PBMC
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Activation and Maturation of Dendritic Cells - PBMC0.032520325 (0.026083467 to 0.042553191)0.037229413 (0.025329726 to 0.052559771)0.022962689 (0.012496152 to 0.035273683)
SecondaryActivation and Maturation of Dendritic Cells - TIL

Measure of expression of activation and maturation of dendritic cells in tumor (TIL).

Time frame:
At Baseline
Reported as:
Median · proportion of immune cells
Activation and Maturation of Dendritic Cells - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Activation and Maturation of Dendritic Cells - TIL0.036315018 (0.029843818 to 0.072159091)0.053093156 (0.04276735 to 0.080816642)0.038510911 (0.018592677 to 0.0664646027278)
SecondaryActivation and Maturation of Dendritic Cells - TIL

Measure of expression of activation and maturation of dendritic cells in tumor (TIL).

Time frame:
At Week 4
Reported as:
Median · proportion of immune cells
Activation and Maturation of Dendritic Cells - TIL
proportion of immune cellsRelatlimabNivolumabRelatlimab + Nivolumab
Activation and Maturation of Dendritic Cells - TIL0.088495575 (0.076190476 to 0.090909091)0.032432432 (0.012600229 to 0.081081081)0.047619048 (0.023310023 to 0.0625)
SecondarySoluble LAG3 Levels - PBMC

Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in blood in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
At the time of disease progression - up to 4 years

No measurements were reported for this outcome.

SecondarySoluble LAG3 Levels - TIL

Amount of LAG3 (cell surface molecule expressed on activated T cells) protein present in tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
At the time of disease progression - up to 4 years

No measurements were reported for this outcome.

SecondaryGranzyme B Serum Levels

Level of granzyme B (a serine protease secreted cells to mediate apoptosis in target cells) in serum.

Time frame:
At 2 weeks prior first study treatment, at 4 weeks, at 12 weeks

No measurements were reported for this outcome.

SecondaryT Cell Count

Number of T cells present in TIL or PBMC.

Time frame:
At 4 weeks

No measurements were reported for this outcome.

SecondaryT Cell Count

Number of T cells present in TIL or PBMC.

Time frame:
At 12 weeks

No measurements were reported for this outcome.

Other pre-specifiedSingle Cell RNA Sequencing

The presence and quantity of RNA in in blood and tumor tissue.

Time frame:
2 weeks

Results for this outcome have not been posted.

Other pre-specifiedSingle Cell RNA Sequencing

The presence and quantity of RNA in in blood and tumor tissue.

Time frame:
At 4 weeks post Cycle 1

Results for this outcome have not been posted.

Other pre-specifiedSingle Cell RNA Sequencing

The presence and quantity of RNA in in blood and tumor tissue.

Time frame:
At week 16 (12 weeks post combination treatment (3 cycles)

Results for this outcome have not been posted.

Other pre-specifiedSingle Cell RNA Sequencing

The presence and quantity of RNA in in blood and tumor tissue in patients that had previously demonstrated complete response (CR), partial response (PR), or stable disease (SD) per RECIST 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
At the time of disease progression - up to 4 years

Results for this outcome have not been posted.

SecondaryT Cell Count

Number of T cells present in TIL or PBMC.

Time frame:
At the time of disease progression - up to 4 years

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events Data, collected for 5 years, 4 months: Relatlimab Arm: combined data for all treatment cycles Nivolumab Arm: combined data for all treatment cycles Relatlimab + Nivolumab Arm: combined data for all treatment cycles All-Cause Mortality - data collected for up to 6 years from patient randomization.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relatlimab8/14 (57.1%)6/14 (42.9%)14/14 (100%)
Nivolumab7/15 (46.7%)9/15 (60%)15/15 (100%)
Relatlimab + Nivolumab5/14 (35.7%)7/14 (50%)14/14 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventRelatlimabNivolumabRelatlimab + Nivolumab
Death NOSGENERAL DISORDERS2/140/150/14
FatigueGENERAL DISORDERS2/142/151/14
HyponatremiaMETABOLISM AND NUTRITION DISORDERS2/141/150/14
HyperglycemiaMETABOLISM AND NUTRITION DISORDERS0/142/151/14
AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS0/140/151/14
HemolysisBLOOD AND LYMPHATIC SYSTEM DISORDERS1/140/150/14
Adrenal insufficiencyENDOCRINE DISORDERS1/140/150/14
Abdominal painGASTROINTESTINAL DISORDERS0/141/151/14
DiarrheaGASTROINTESTINAL DISORDERS0/141/151/14
NauseaGASTROINTESTINAL DISORDERS0/141/151/14
Most frequent other events
Showing 10 of 204
Most frequent other events
EventRelatlimabNivolumabRelatlimab + Nivolumab
FatigueGENERAL DISORDERS11/149/1511/14
HyponatremiaMETABOLISM AND NUTRITION DISORDERS11/149/1511/14
AnemiaBLOOD AND LYMPHATIC SYSTEM DISORDERS9/148/159/14
Blood lactate dehydrogenase increasedINVESTIGATIONS8/149/158/14
NauseaGASTROINTESTINAL DISORDERS8/147/158/14
Weight lossINVESTIGATIONS8/143/158/14
HyperglycemiaMETABOLISM AND NUTRITION DISORDERS4/148/154/14
Sinus bradycardiaCARDIAC DISORDERS6/144/156/14
Aspartate aminotransferase increasedINVESTIGATIONS6/144/156/14
Creatinine increasedINVESTIGATIONS6/142/156/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)RelatlimabNivolumabRelatlimab + NivolumabTotal
Median70.00 (53.00 to 76.00)69.00 (35.00 to 88.00)60.00 (38.00 to 87.00)67.00 (35.00 to 88.00)
Sex: Female, Male
Sex: Female, Male(Participants)RelatlimabNivolumabRelatlimab + NivolumabTotal
Female47415
Male1081028
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RelatlimabNivolumabRelatlimab + NivolumabTotal
Hispanic or Latino0000
Not Hispanic or Latino14151443
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RelatlimabNivolumabRelatlimab + NivolumabTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White14151443
More than one race0000
Unknown or Not Reported0000
BRAF.STATUS
BRAF.STATUS(Participants)RelatlimabNivolumabRelatlimab + NivolumabTotal
Wild-Type49720
Mutated75618
Unknown3115
08

Study locations

1 site
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jul 2024, 63 months.

Results were first posted in Aug 2026, 2 years 1 month after primary completion.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's 63 months is close to that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Nov 16, 2018
StartActual
Mar 29, 2019
Primary completionActual
Jul 3, 2024
CompletionActual
Jul 3, 2025
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03743766
Lead sponsor
John Kirkwood
Responsible party
John Kirkwood (Usher Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Nov 16, 2018
Start date
Mar 29, 2019
Primary completion
Jul 3, 2024
Completion
Jul 3, 2025
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

John Kirkwood, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Relatlimab · Nivolumab

Start the discussion